Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

The new GLP-1 pills are likely to boost consumer demand for these popular weight-loss drugs. But it could also signal bad news for employees who want their employer-sponsored health insurance plan to foot the bill. Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly's pill, Foundayo , began shipping in April. While many industry watchers were hoping the oral equivalents would be more financially palatable, they're roughly the same cost as injectables for employers that offer them through insurance. This, coupled with the fact that more people are likely to be interested in a pill rather than a shot, is giving employers pause. Notably, a Business Group on Health survey fielded earlier this year found that 87% of employers expect the availability of oral medications to increase demand for GLP-1s, while only 9% predict a price drop. In 2025, nearly half of all large employers covered GLP-1 medications approved for weight loss, according to Mercer. But costs are becoming prohibitive. In NFP's recent annual employer survey , 51% of employers cited GLP-1s as the top driver of rising prescription drug costs. "Employers say the rise in pharmacy costs is unsustainable," said Nick Conway, president of Rx Solutions at NFP, a global benefits consultant. …